Eleven harnesses combinatorial chemistry and AI to transform RNAi drug development into a programmable process, targeting diseases including influenza and SARS-CoV-2. Founded in 2020 in Cambridge, United Kingdom, the company has raised $22.0M in seed funding from investors including Gates, Kindred Capital, and Entree Capital. AI-based RNA drug development platform for researchers. The company harnesses the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process against influenza and SARS-CoV-2. Founded in 2020, headquartered in Cambridge, United Kingdom. The team comprises 17 (Jun 30, 2026) employees. Backed by investors including Gates, Kindred Capital, Entree Capital, Harel Group. The company is tagged with Te.
Eleven
SeedEleven harnesses combinatorial chemistry and AI to transform RNAi drug development into a programmable process, targeting diseases including influenza and SARS-CoV-2. Founded in 2020 in Cambridge, United Kingdom, the company has raised $22.0M in seed funding from investors including Gates, Kindred Capital, and Entree Capital. AI-based RNA drug development platform for researchers. The company harnesses the power of…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Drug Development,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > Tel Aviv University
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Full list of active funds — filter by stage, check size, and geography.